Canada markets open in 5 hours 14 minutes

Canntab Therapeutics Limited (CTABF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.5681+0.0186 (+3.38%)
At close: 9:45AM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.5495
Open0.5681
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.5681 - 0.5681
52 Week Range0.4620 - 0.8940
Volume1,000
Avg. Volume1,184
Market Cap20.417M
Beta (5Y Monthly)1.32
PE Ratio (TTM)N/A
EPS (TTM)-0.1030
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateMar. 08, 2016
1y Target EstN/A
  • CNW Group

    Canntab Reaches Agreement with Innovative Bioinformatics Company, 36eight Technologies Inc.

    Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that it has reached an agreement (the "Agreement") with 36Eight Technologies Inc. ("36Eight"), a growing bioinformatics pharmacological healthcare data and technology company, which has developed a proprietary artificial intelligence and machine learning algorithm which

  • CNW Group

    Canntab Announces the Early Exercise of $1,259,250 Warrants

    Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce the receipt of C$1,259,250 in gross proceeds from the early exercise of 1,679,000 warrants into common shares (the "Warrants"). The Warrants were issued in the final week of May and each Warrant was exercised into 1 common share in the capital of the Company at $0.75. T

  • CNW Group

    Canntab Mourns the Loss of Co-Founder

    Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, announces, with very heavy hearts, the passing of Jeffrey Ward Renwick, the Company's Co-Founder, Director and President. After a long and difficult 15 month battle, Jeff succumbed to his lung cancer at the young age of 54 years.